Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
---|---|
Information provided by: | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
ClinicalTrials.gov Identifier: | NCT00004552 |
This study will examine whether pretreatment with two doses of acamprosate for seven days prior to abstinence lessens the intensity of acute withdrawal from alcohol compared with a placebo. Subjects will be randomly assigned to receive either one of two doses of acamprosate or placebo for seven days. This will be followed by a four- day inpatient period when withdrawal will be monitored. Additional drinking information will be obtained at a three month followup interview.
Condition | Intervention | Phase |
---|---|---|
Alcoholism |
Drug: acamprosate (Campral) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Placebo Control, Efficacy Study |
Official Title: | Etiology and Treatment of Alcohol Dependence |
Ages Eligible for Study: | 21 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | NIAAAOMA03510 |
Study First Received: | February 3, 2000 |
Last Updated: | November 4, 2005 |
ClinicalTrials.gov Identifier: | NCT00004552 History of Changes |
Health Authority: | United States: Federal Government |
Mental Disorders Alcoholism Substance-Related Disorders Disorders of Environmental Origin |
Alcohol-Related Disorders Acamprosate Ethanol |
Mental Disorders Therapeutic Uses Alcoholism Substance-Related Disorders Disorders of Environmental Origin |
Alcohol-Related Disorders Central Nervous System Agents Pharmacologic Actions Alcohol Deterrents Acamprosate |